Previous 10 | Next 10 |
home / stock / hnsbf / hnsbf news
LUND, Sweden , Jan. 13, 2020 /PRNewswire/ -- Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced a business update for the fourth quarter 2019 and preliminary, unaudited key financials for its financial year 2019. ...
LUND, Sweden , Dec. 13, 2019 /PRNewswire/ -- Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, today announced the outcome of a November 20th meeting with the U.S. Food and Drug Administration (FDA) to discuss a regulatory path forward for...
Hansa Biopharma AB ( OTC:HNSBF ): Q3 GAAP EPS of -SEK2.36. More news on: Hansa Biopharma AB (publ), Earnings news and commentary, Read more ...
MALMÖ, Sweden , Oct. 31, 2019 /PRNewswire/ -- - Positive results from a pooled analysis of Phase 2 trials with imlifidase for desensitization in highly sensitized kidney transplant patients were presented for the first time at the European Society of Organ Transplantation's (ESOT) ...
LUND, Sweden , Oct. 11, 2019 /PRNewswire/ -- Hansa Biopharma will publish its interim report for the first nine months of 2019 at 8:00 a.m. CET on October 31, 2019 . All interested parties are invited to participate in a telephone conference, which will include a presentation of the in...
LUND, Sweden , Sept. 25, 2019 /PRNewswire/ -- Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, today announced that a date for a follow- up meeting with the U.S. Food and Drug Administration (FDA) has now been confirmed. The meeting will ta...
LUND, Sweden , Sept. 18, 2019 /PRNewswire/ -- Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced that positive imlifidase data were highlighted in a presentation at the 19th Congress of the European Society for Organ Transplantation...
LUND, Sweden , Aug. 30, 2019 /PRNewswire/ -- Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that new imlifidase data will be highlighted in a presentation at the 19th Congress of the European Society for Organ Transplantat...
LUND, Sweden , Aug. 21, 2019 /PRNewswire/ -- Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that the Company's management team will participate in the following upcoming investor conferences: The Goldman Sachs Ninth Ann...
Hansa Biopharma AB ( OTC:HNSBF ): Q2 GAAP EPS of -SEK2.06. More news on: Hansa Biopharma AB (publ), Earnings news and commentary, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Hansa Biopharma AB Company Name:
HNSBF Stock Symbol:
OTCMKTS Market:
Hansa Biopharma to present data at 2024 American Transplant Congress annual meeting PR Newswire LUND , Sweden , May 21, 2024 /PRNewswire/ --. Hansa Biopharma, "Hansa" (NASDAQ: HNSA) (STOCKHOLM: HNSA), today announced data featuring imlifidase will be present...
Imlifidase met primary endpoint in 16-HMedIdes-12 phase 2 trial in patients with AMR following kidney transplantation PR Newswire Statistically significant reduction in donor-specific antibodies (DSAs) observed among imlifidase patients within five days of treatment as compared ...
Hansa Biopharma interim report January-March 2023 PR Newswire Positive reimbursement decision in Spain expands market access to include the five largest European markets Enrollment in phase 2 study of imlifidase in Guillain-Barré Syndrome (GBS) completed HNSA-...